Drugs / Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells
Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02659943 | Jan 2016 → Jun 2018 | B-cell non-Hodgkin lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02659943 ↗ |
| Action | Deplete | “T cells can destroy tumors.” NCT02659943 ↗ |
| Modality | Cell therapy | “T-cells obtained by leukapheresis will be genetically modified to express an anti-CD19 CAR” NCT02659943 ↗ |
| Route | Intravenous | “They will get the T cells through the IV in 1 infusion.” NCT02659943 ↗ |